289 related articles for article (PubMed ID: 16320157)
1. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.
Dittrich R; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Mueller A
Exp Clin Endocrinol Diabetes; 2005 Dec; 113(10):586-92. PubMed ID: 16320157
[TBL] [Abstract][Full Text] [Related]
2. Effects on the male endocrine system of long-term treatment with gonadotropin-releasing hormone agonists and estrogens in male-to-female transsexuals.
Mueller A; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Dittrich R
Horm Metab Res; 2006 Mar; 38(3):183-7. PubMed ID: 16673210
[TBL] [Abstract][Full Text] [Related]
3. Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist.
Mueller A; Zollver H; Kronawitter D; Oppelt PG; Claassen T; Hoffmann I; Beckmann MW; Dittrich R
Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):95-100. PubMed ID: 20625973
[TBL] [Abstract][Full Text] [Related]
4. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone.
Mueller A; Dittrich R; Binder H; Kuehnel W; Maltaris T; Hoffmann I; Beckmann MW
Eur J Endocrinol; 2005 Jul; 153(1):107-13. PubMed ID: 15994752
[TBL] [Abstract][Full Text] [Related]
5. [Morbidity in transsexual patients with cross-gender hormone self-treatment].
Becerra Fernández A; de Luis Román DA; Piédrola Maroto G
Med Clin (Barc); 1999 Oct; 113(13):484-7. PubMed ID: 10604171
[TBL] [Abstract][Full Text] [Related]
6. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals.
Mueller A; Haeberle L; Zollver H; Claassen T; Kronawitter D; Oppelt PG; Cupisti S; Beckmann MW; Dittrich R
J Sex Med; 2010 Sep; 7(9):3190-8. PubMed ID: 20584125
[TBL] [Abstract][Full Text] [Related]
7. Hormone treatment of the adult transsexual patient.
Gooren L
Horm Res; 2005; 64 Suppl 2():31-6. PubMed ID: 16286768
[TBL] [Abstract][Full Text] [Related]
8. The effect of cross-gender hormonal treatment on bone metabolism in male-to-female transsexuals.
Lips P; Asscheman H; Uitewaal P; Netelenbos JC; Gooren L
J Bone Miner Res; 1989 Oct; 4(5):657-62. PubMed ID: 2530804
[TBL] [Abstract][Full Text] [Related]
9. The sex difference of plasma homovanillic acid is unaffected by cross-sex hormone administration in transsexual subjects.
Giltay EJ; Kho KH; Blansjaar BA; Verbeek MM; Geurtz PB; Geleijnse JM; Gooren LJ
J Endocrinol; 2005 Oct; 187(1):109-16. PubMed ID: 16214946
[TBL] [Abstract][Full Text] [Related]
10. Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
van Kesteren PJ; Asscheman H; Megens JA; Gooren LJ
Clin Endocrinol (Oxf); 1997 Sep; 47(3):337-42. PubMed ID: 9373456
[TBL] [Abstract][Full Text] [Related]
11. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers.
Weitzel JN; Buys SS; Sherman WH; Daniels A; Ursin G; Daniels JR; MacDonald DJ; Blazer KR; Pike MC; Spicer DV
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):654-8. PubMed ID: 17255289
[TBL] [Abstract][Full Text] [Related]
12. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people.
Toorians AW; Thomassen MC; Zweegman S; Magdeleyns EJ; Tans G; Gooren LJ; Rosing J
J Clin Endocrinol Metab; 2003 Dec; 88(12):5723-9. PubMed ID: 14671159
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.
Gooren LJ; Giltay EJ; Bunck MC
J Clin Endocrinol Metab; 2008 Jan; 93(1):19-25. PubMed ID: 17986639
[TBL] [Abstract][Full Text] [Related]
14. Handedness, functional cerebral hemispheric lateralization, and cognition in male-to-female transsexuals receiving cross-sex hormone treatment.
Wisniewski AB; Prendeville MT; Dobs AS
Arch Sex Behav; 2005 Apr; 34(2):167-72. PubMed ID: 15803250
[TBL] [Abstract][Full Text] [Related]
15. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
16. Influence of exogenous oestrogen or (anti-) androgen administration on soluble transferrin receptor in human plasma.
T'Sjoen GG; Beguin Y; Feyen E; Rubens R; Kaufman JM; Gooren L
J Endocrinol; 2005 Jul; 186(1):61-7. PubMed ID: 16002536
[TBL] [Abstract][Full Text] [Related]
17. The effect of androgen treatment on bone metabolism in female-to-male transsexuals.
Lips P; van Kesteren PJ; Asscheman H; Gooren LJ
J Bone Miner Res; 1996 Nov; 11(11):1769-73. PubMed ID: 8915785
[TBL] [Abstract][Full Text] [Related]
18. Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual.
García-Malpartida K; Martín-Gorgojo A; Rocha M; Gómez-Balaguer M; Hernández-Mijares A
Fertil Steril; 2010 Aug; 94(3):1097.e13-5. PubMed ID: 20227072
[TBL] [Abstract][Full Text] [Related]
19. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.
Asscheman H; Giltay EJ; Megens JA; de Ronde WP; van Trotsenburg MA; Gooren LJ
Eur J Endocrinol; 2011 Apr; 164(4):635-42. PubMed ID: 21266549
[TBL] [Abstract][Full Text] [Related]
20. Effects of sex steroids on the neurotransmitter-specific aromatic amino acids phenylalanine, tyrosine, and tryptophan in transsexual subjects.
Giltay EJ; Bunck MC; Gooren LJ; Zitman FG; Diamant M; Teerlink T
Neuroendocrinology; 2008; 88(2):103-10. PubMed ID: 18511863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
